These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 12180490

  • 1. A personal history of the CAMPATH-1H antibody.
    Waldmann H.
    Med Oncol; 2002; 19 Suppl():S3-9. PubMed ID: 12180490
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
    Williams RJ, Clarke E, Blair A, Evely R, Hale G, Waldmann H, Brookes S, Pamphilon DH.
    Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
    [Abstract] [Full Text] [Related]

  • 5. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
    Osterborg A, Werner A, Halapi E, Lundin J, Harmenberg U, Wigzell H, Mellstedt H.
    Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
    [Abstract] [Full Text] [Related]

  • 6. Alemtuzumab in stem cell transplantation.
    Hale G.
    Med Oncol; 2002 Jan; 19 Suppl():S33-47. PubMed ID: 12180491
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
    Alinari L, Lapalombella R, Andritsos L, Baiocchi RA, Lin TS, Byrd JC.
    Oncogene; 2007 May 28; 26(25):3644-53. PubMed ID: 17530018
    [Abstract] [Full Text] [Related]

  • 9. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
    Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H.
    J Clin Oncol; 1997 Apr 28; 15(4):1567-74. PubMed ID: 9193354
    [Abstract] [Full Text] [Related]

  • 10. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
    Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D.
    Leuk Res; 1998 Feb 28; 22(2):185-91. PubMed ID: 9593475
    [Abstract] [Full Text] [Related]

  • 11. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ.
    Expert Rev Anticancer Ther; 2002 Feb 28; 2(1):23-35. PubMed ID: 12113063
    [Abstract] [Full Text] [Related]

  • 12. Rediscovering alemtuzumab: current and emerging therapeutic roles.
    Gribben JG, Hallek M.
    Br J Haematol; 2009 Mar 28; 144(6):818-31. PubMed ID: 19183194
    [Abstract] [Full Text] [Related]

  • 13. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
    Pangalis GA, Dimopoulou MN, Angelopoulou MK, Tsekouras C, Vassilakopoulos TP, Vaiopoulos G, Siakantaris MP.
    Med Oncol; 2001 Mar 28; 18(2):99-107. PubMed ID: 11778765
    [Abstract] [Full Text] [Related]

  • 14. Advances in the use of alemtuzumab in CLL.
    Stilgenbauer S.
    Clin Adv Hematol Oncol; 2008 Jan 28; 6(1):23-4. PubMed ID: 18322437
    [No Abstract] [Full Text] [Related]

  • 15. Campath-1H monoclonal antibody therapy.
    Flynn JM, Byrd JC.
    Curr Opin Oncol; 2000 Nov 28; 12(6):574-81. PubMed ID: 11085457
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of CAMPATH-1H in BMT patients.
    Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G.
    Cytotherapy; 2001 Nov 28; 3(4):261-7. PubMed ID: 12171714
    [Abstract] [Full Text] [Related]

  • 17. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA.
    Cancer Res; 2003 Oct 01; 63(19):6453-7. PubMed ID: 14559836
    [Abstract] [Full Text] [Related]

  • 18. Alemtuzumab therapy in B-cell lymphoproliferative disorders.
    Moreton P, Hillmen P.
    Semin Oncol; 2003 Aug 01; 30(4):493-501. PubMed ID: 12939718
    [Abstract] [Full Text] [Related]

  • 19. Alemtuzumab in T-cell malignancies.
    Dearden CE, Matutes E, Catovsky D.
    Med Oncol; 2002 Aug 01; 19 Suppl():S27-32. PubMed ID: 12180489
    [Abstract] [Full Text] [Related]

  • 20. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
    Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M.
    Cancer; 2004 Sep 01; 101(5):999-1008. PubMed ID: 15329909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.